- Home
- GNLX vs IKT Comparison
GNLX vs IKT Comparison
Compare GNLX & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- IKT
- Stock Information
- Founded
- GNLX 2001
- IKT 2008
- Country
- GNLX United States
- IKT United States
- Employees
- GNLX N/A
- IKT N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- IKT Health Care
- Exchange
- GNLX Nasdaq
- IKT Nasdaq
- Market Cap
- GNLX 184.4M
- IKT 167.2M
- IPO Year
- GNLX 2023
- IKT 2020
- Fundamental
- Price
- GNLX $2.63
- IKT $1.90
- Analyst Decision
- GNLX Strong Buy
- IKT Buy
- Analyst Count
- GNLX 4
- IKT 2
- Target Price
- GNLX $18.25
- IKT $8.00
- AVG Volume (30 Days)
- GNLX 233.3K
- IKT 147.0K
- Earning Date
- GNLX 05-08-2025
- IKT 05-14-2025
- Dividend Yield
- GNLX N/A
- IKT N/A
- EPS Growth
- GNLX N/A
- IKT N/A
- EPS
- GNLX N/A
- IKT N/A
- Revenue
- GNLX $8,000.00
- IKT N/A
- Revenue This Year
- GNLX N/A
- IKT N/A
- Revenue Next Year
- GNLX N/A
- IKT N/A
- P/E Ratio
- GNLX N/A
- IKT N/A
- Revenue Growth
- GNLX N/A
- IKT N/A
- 52 Week Low
- GNLX $1.60
- IKT $1.12
- 52 Week High
- GNLX $5.89
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- GNLX 42.31
- IKT 42.84
- Support Level
- GNLX $2.30
- IKT $1.58
- Resistance Level
- GNLX $2.68
- IKT $2.22
- Average True Range (ATR)
- GNLX 0.26
- IKT 0.22
- MACD
- GNLX 0.05
- IKT 0.00
- Stochastic Oscillator
- GNLX 55.49
- IKT 45.57
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.